Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01428180
Recruitment Status : Completed
First Posted : September 2, 2011
Last Update Posted : April 6, 2016
Information provided by (Responsible Party):
Manuel Schmid, University of Ulm

Brief Summary:
The purpose of this study is to examine the influence medical or surgical treatment for patent ductus arteriosus in preterm infants on cerebral and renal tissue oxygenation and on cardiac output.

Condition or disease Intervention/treatment
Prematurity of Fetus Patent Ductus Arteriosus Drug: Indomethacin Procedure: Surgical Ligation Drug: Ibuprofen

Detailed Description:

In this observational trial the investigators want to examine whether clinical or echocardiographic parameters of patent ductus arteriosus are related to

  • cerebral tissue oxygen saturation, total hemoglobin, fractional tissue oxygen extraction and HbD
  • renal tissue oxygen saturation, total hemoglobin, fractional tissue oxygen extraction and HbD

as measured by near infrared spectroscopy

and to

  • stroke volume
  • cardiac output

as measured by electrical cardiometry.

The investigators want to examine the impact of surgical and medical treatment for patent ductus on these parameters. The investigators want to compare the change of these parameters between responders to medical treatment and nonresponders.

Study Type : Observational
Actual Enrollment : 35 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Changes of Cerebral Tissue Oxygen Saturation During Treatment of Patent Ductus Arteriosus in Neonates
Study Start Date : April 2011
Actual Primary Completion Date : October 2012
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Infants treated with Indomethacin
Drug: Indomethacin
3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)

Infants treated with Ibuprofen
Drug: Ibuprofen
3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg

Infants undergoing surgical ligation
Procedure: Surgical Ligation
In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.

Primary Outcome Measures :
  1. Change of cerebral tissue oxygen saturation during treatment for patent ductus arteriosus [ Time Frame: from 10 minutes before start of infusion until 4 hours after end of transfusion ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 34 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Preterm neonates with patent ductus arteriosus treated in our hospital

Inclusion Criteria:

  • Newborn infant below 34 weeks postmenstrual age at the time of birth
  • Patent ductus arteriosus with signs of hemodynamic relevance (as judged by the attending neonatologist)
  • parental informed consent

Exclusion Criteria:

  • Patent ductus arteriosus as part of malformation syndrome
  • Additional major cardiovascular malformations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01428180

University Medical Center
Ulm, Baden-Württemberg, Germany, 89075
Sponsors and Collaborators
University of Ulm
Principal Investigator: Manuel B Schmid, Dr. med. University of Ulm

Responsible Party: Manuel Schmid, Dr. med., University of Ulm Identifier: NCT01428180     History of Changes
Other Study ID Numbers: ULMNEONIRS03
First Posted: September 2, 2011    Key Record Dates
Last Update Posted: April 6, 2016
Last Verified: April 2016

Keywords provided by Manuel Schmid, University of Ulm:
preterm neonates
hemodynamically relevant patent ductus arteriosus

Additional relevant MeSH terms:
Ductus Arteriosus, Patent
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Gout Suppressants
Tocolytic Agents
Reproductive Control Agents